SCIENTIFIC HUB

Follow the evidence.

SCIENTIFIC LITERATURE · MED

Acalculous cholecystitis associated with levodopa-carbidopa intestinal infusion therapy: A case report.

Clin Park Relat Disord · 2022-07-01

DOI: 10.1016/j.prdoa.2022.100150PMID: 35856047

Open accessJournal Article; Case Reports; case-reportOriginal source ↗

Research overview

The text below is the source article’s original abstract under a verified reuse license. cc by

Continuous intra jejunal infusion of levodopa-carbidopa intestinal gel (LCIG) is one of the primary therapies for improving advanced Parkinson's disease symptoms. Placement of the jejunal catheter through the abdominal wall for drug administration requires a percutaneous interventional procedure called percutaneous endoscopic gastrostomy (PEG). PEG is considered a safe and straightforward procedure, and it is performed very commonly in clinical practice. In the context of LCIG treatment, severe adverse events have been identified, such as intestinal bleeding and acute abdomen [1], but acute acalculous cholecystitis (AAC) has never been reported.

Scientific assessment

01

Research question

Assess the question within the original study’s scope.

02

Methods & sample

Check the source article for study design and sample details.

03

Key findings

An editorially approved findings summary is not yet published for this record.

04

Limitations

Generalizability, bias and clinical meaning require separate assessment.

Methods, samples and clinical conclusions are not inferred from bibliographic metadata.